article thumbnail

2025: A year of stricter rules, course corrections?

Express Pharma

Will 2025 see a more vigilant government when it comes to violations by pharma companies, be it GMP slip ups or the Uniform Code of Pharmaceutical Manufacturing Practices (UCPMP)? 2025 could thus be a pivotal year for course corrections for all stakeholders. VIVEKA ROYCHOWDHURY, Editor viveka.r@expressindia.com

article thumbnail

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

Drug Channels

This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. The Leadership Forum will be an executive gathering where drug channel leaders can network and discuss key issues and challenges facing the commercial healthcare system.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. The company hopes to produce this number tenfold by the end of 2030.

article thumbnail

WuXi STA breaks ground on new Delaware manufacturing facility

European Pharmaceutical Review

Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. The WuXi STA Middletown facility is expected to begin operations in 2025.

article thumbnail

Novo Nordisk plans multi-billion Denmark manufacturing expansion

European Pharmaceutical Review

The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.

Packaging 111
article thumbnail

AstraZeneca partnership to pioneer UK’s first commercial biomethane supply

European Pharmaceutical Review

Once operational in early 2025, the partnership will reduce emissions by an estimated 20,000 tonnes CO 2 equivalent (CO 2 e). Alongside this move, AstraZeneca’s investment in major energy efficiencies in its operations, brings the total of its financial commitment to net zero, to £100 million.

article thumbnail

AbbVie Cork facility €60 million expansion

European Pharmaceutical Review

AbbVie , an international R&D biopharmaceutical enterprise has celebrated its 20th anniversary by investing in extensive renovations at its manufacturing site in Cork, Ireland. The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025.